AlphaFold predicted structure
ST3GAL3 · Q11203

Mean pLDDT
90.9/ 100
Very high
375 residues
Confidence breakdown
- Very high(≥ 90)74%
- Confident(70–90)21%
- Low(50–70)1%
- Very low(< 50)4%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
ST3 beta-galactoside alpha-2,3-sialyltransferase 3
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
infantile spasms
autosomal recessive non-syndromic intellectual disability
genetic developmental and epileptic encephalopathy
early-infantile DEE
COVID-19
neurodegenerative disease
hereditary disease
developmental and epileptic encephalopathy
attention deficit-hyperactivity disorder
severe acute respiratory syndrome
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase
Catalyzes the formation of the NeuAc-alpha-2,3-Gal-beta-1,4-GlcNAc-, NeuAc-alpha-2,3-Gal-beta-1,3-GlcNAc- and NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc- sequences found in terminal carbohydrate groups of glycoproteins and glycolipids. The highest activity is toward Gal-beta-1,3-GlcNAc and the lowest toward Gal-beta-1,3-GalNAc
ST3GAL3 · Q11203

Mean pLDDT
90.9/ 100
Very high
375 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0